News

Need CME credit? We've got you covered.

Explore innovative approaches to mental health care, from jail diversion programs to addressing burnout in female physicians, enhancing patient outcomes.

Review the news from this year's Clinical Trials in Alzheimer's Disease conference.

A psychiatric reflects on a true gift, envisioning a future of hope, healing, and inclusion and celebrating the power of unity and compassion.

See the variety of commentary, news, and happenings in artificial intelligence (AI) and psychiatry throughout this year.

Syremis Therapeutics advances innovative drugs ST-905 and ST-901 for schizophrenia and major depressive disorder, aiming to transform mental health treatment.

During the holidays, can we blend tradition with modern media habits without sacrificing the meaning?

Cobenfy gains NMPA approval in China, offering a groundbreaking treatment for schizophrenia with a unique mechanism and improved symptom management.

In this CME article, explore effective strategies for managing sleep disturbances in elite athletes, focusing on pharmacologic and nonpharmacologic interventions.

Reviva Pharmaceuticals announced FDA recommendations from their pre-NDA meeting on brilaroxazine for schizophrenia.

Discover engaging holiday reads that blend entertainment with profound insights, featuring classics and modern works that explore the human psyche.

An open letter urges lawmakers to regulate AI chatbots, highlighting their dangers to children's emotional development and mental health.

Let's examine the vital intersection of religion, spirituality, and mental health, revealing their powerful role in enhancing patient care and well-being.

The tragedy sheds light on the complexities of parricide and loss.

Discover how access to nature enhances mental health, promoting healing and resilience through green spaces and innovative therapeutic practices.

Explore the transformative impact of lifestyle psychiatry on mental health, emphasizing exercise, nutrition, and connectedness for improved well-being in our latest Special Report.

Explore the legacies of Milwaukee's influential psychiatrists, Jon Gudeman and Scott Sandage, and their impact on mental health and culture.

Vistagen's fasedienol fails to show significant efficacy in treating social anxiety disorder, despite favorable safety data from the PALISADE-3 trial.

Explore innovative strategies for managing schizophrenia, focusing on novel treatments that address negative and cognitive symptoms beyond traditional antipsychotics.

Explore Irvin D. Yalom's impactful insights on psychotherapy, revealing the emotional dynamics between therapist and patient in transformative narratives.

Discover new research on schizophrenia treatments, including digital therapeutics and valbenazine, showcasing significant improvements in patient outcomes.

AI chatbots pose significant privacy risks as user data becomes proprietary, raising concerns about exploitation and data security in a digital landscape.

Explore the vital contributions of psychiatry, from therapeutic alliances to ethical principles, and the future challenges it faces in a complex world.

AFSP's new CAPS program empowers health care professionals with essential skills to identify and support patients at risk for suicide effectively.

Frank A. Clark, MD, reflects on current events using poetry.

Learn how to critically analyze randomized controlled trials to ensure trustworthy results and improve clinical decision-making in mental health care.

Let's explore the therapeutic value of fear, including how embracing anxiety enhances creativity and personal growth in artists and therapists alike.

The article explores the psychological impact of recent mass killings, highlighting societal issues like anti-Semitism and mental health, while calling for collective healing.

Roche reveals promising results for trontinemab, an Alzheimer antibody, showing significant amyloid plaque reduction in patients during ongoing trials.